Jan. 29, 2003 — In May 2002, Medscape reported on the Medical Therapy of Prostatic Symptoms (MTOPS) Trial, which suggested a definite benefit to combining finasteride and doxazosin for the treatment ...

May 31, 2002 -- Combining finasteride with doxazosin substantially reduces progression of benign prostatic hyperplasia (BPH) compared with either drug alone, and the combination should become the ...

Finasteride treatment reduces the risk of low-grade prostate cancer (PCa) in men taking the drug for symptomatic benign prostatic hyperplasia (BPH), data show. Teemu J. Murtola, MD, of the University ...

Objective: The purpose of this study was to examine the rates of acute urinary retention (AUR) and surgery after initiating 5-alpha reductase inhibitor (5ARI) therapy and to compare the 2 currently ...

“Our results are generally comparable to [those of] the PCPT, despite differences in study populations” The Prostate Cancer Prevention Trial (PCPT) showed that the use of finasteride, a 5α reductase ...

ATLANTA—One year of finasteride treatment can decrease PSA levels and prostate volume significantly in men with benign prostatic hyperplasia (BPH), and the magnitude of change may improve clinicians’ ...

MIAMI, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that the clinical trial of the Company’s proprietary Tadalafil and ...

INDIANAPOLIS, March 18, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) presented results today at the annual European Association of Urology (EAU) Congress in Milan, Italy, of a study that ...

Two types of drug are used to manage benign prostatic hyperplasia (BPH). Alpha blockers, such as alfuzosin, indoramin, prazosin, tamsulosin and terazosin, relieve lower urinary tract symptoms (LUTS) ...